Lifecore Biomedical Secures Manufacturing Agreement with Indomo for Acne Treatment

Lifecore Biomedical Inc. (Nasdaq: LBI) announced a new partnership with Indomo to manufacture batches of an innovative drug/device combination acne treatment. The agreement, disclosed on March 4, 2026, positions Lifecore to expand its contract development and manufacturing services (CDMO) within the dermatology segment of the health‑care market.

Key Terms of the Agreement

  • Scope of Work: Lifecore will produce sterile injectable pharmaceutical products—specifically the acne treatment in syringes and vials—under Indomo’s formulation.
  • Production Capacity: The contract includes multiple production runs to meet anticipated commercial demand.
  • Geographic Reach: Lifecore’s manufacturing sites will supply the treatment for distribution worldwide, aligning with Indomo’s global launch strategy.

Strategic Significance

  • Portfolio Expansion: The collaboration extends Lifecore’s expertise beyond its traditional offerings of pharmaceutical‑grade sodium hyaluronate and sterile injectables, adding a high‑margin dermatology product.
  • Revenue Impact: While financial terms are undisclosed, the partnership is expected to contribute to Lifecore’s top‑line growth in the upcoming fiscal year.
  • Market Positioning: By partnering with a developer of a drug/device combination, Lifecore reinforces its reputation as a versatile CDMO capable of handling complex, regulated products.

Company Background

Founded in 1996 and listed on the Nasdaq, Lifecore Biomedical specializes in contract development and manufacturing of sterile pharmaceutical products. Its product line includes injectable syringes, vials, and pharmaceutical‑grade sodium hyaluronate, serving customers worldwide. The company’s market capitalization stands at approximately $270 million USD, with a current share price of $6.99.

Outlook

The agreement with Indomo is anticipated to strengthen Lifecore’s foothold in the dermatology sector and provide a platform for further collaborations in drug/device combination therapies. The partnership aligns with the company’s broader strategy to diversify its manufacturing portfolio and enhance global market penetration.